This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”
christine.book Mon, 06/26/2023 - 12:46 June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting.
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Research suggests that the accumulation of these proteins is a continuous process that starts decades before the onset of symptoms.
Anderson , PhD, a trailblazer in nuclearmedicine, has been named the 2024 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. The award was announced by the Society of NuclearMedicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto.
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma, according to a study published October 24 in the Journal of NuclearMedicine. One of 10 had complete remission, one of 10 had partial remission, and eight of 10 had stable disease.
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with high-efficacy disease-modifying therapies, according to a recent study by researchers in Boston. Image courtesy of Clinical NuclearMedicine.
For patients with interstitial lung disease, FAPI PET/CT was more effective than 18F-FDG PET/CT at predicting progressive pulmonary fibrosis according to comparative study findings presented at the 2024 Society of NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting.
milla1cf Tue, 06/11/2024 - 18:41 June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the “Alzheimer’s disease of the heart.” This research was presented at the 2024 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
PET/CT imaging with F-18 sodium fluoride (NaF) is emerging as a sensitive tool for detecting early atherosclerosis, according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of NuclearMedicine. but presented no evidence for primary tumor. (B)
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclearmedicine, diagnostic radiology, and radiation oncology.
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of NuclearMedicine and Molecular Imaging (SNMMI) meeting in Toronto. Image courtesy of SNMMI.
Mahmood was presented the award by the Society of NuclearMedicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. Award recipients will have initiated, developed, and successfully implemented unique and significant transformative value within the field of nuclearmedicine and molecular imaging.
This is just the third year that RSNA has offered a dedicated track on nuclearmedicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Can AI help?
An emerging PET/CT radiotracer may be more predictive of progressive pulmonary fibrosis in interstitial lung patients than F-18 FDG PET/CT, according to research presented June 8 at the 2024 Society of NuclearMedicine and Molecular Imaging Annual Meeting (SNMMI).
His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Dmitry Beyder.
milla1cf Fri, 02/09/2024 - 09:17 February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before clinical symptoms arise, according to research published in the February issue of The Journal of NuclearMedicine. It is a complex autoimmune disease characterized by chronic inflammation.
A recently developed PET radiotracer identified sources of pain in patients with complex regional pain syndrome (CRPS) and led to effective treatments, according to a study presented June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
christine.book Mon, 06/26/2023 - 11:55 June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed its ability to successfully detect metastatic pancreatic cancer and visualize targeted treatment of the disease.
CHICAGO – Gallium-68 (Ga-68) RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented November 26 at RSNA 2023. Therefore, Ga-68 RM2-PET should be considered in addition to PSMA-PET in BCR prostate cancer patients to aid in disease detection and management decision, she suggested.
PET/CT is poised to become a key tool for imaging the coronary arteries – a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain, experts say. Coronary artery disease (CAD) is the leading cause of mortality in the U.S.
The Society’s flagship journal, Radiology , is the world’s foremost journal for new, important and translatable discoveries in medical imaging research and provides meaningful information to medical imaging physicians and scientists aiming to improve health and reduce the burden of disease. It is the most cited journal in its field.
It's only been a few years since a dedicated track in nuclearmedicine and molecular imaging was established at the meeting, and the practice already dominates it. They appear promising for detecting liver cancer, bladder cancer, breast cancer, and interstitial lung disease. Below is just a sample of the content on offer.
Katherine Zukotynski, MD, PhD, of McMaster University in Hamilton, Ontario, has been awarded the American College of NuclearMedicines (ACNM) 2025 Lifetime Achievement Award. Her main areas of research are in PET/CT applications in oncology, neurodegenerative disease, and machine learning,McMastersaid.
mtaschetta-millane Sun, 06/25/2023 - 14:00 June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated, according to research presented at the 2023 Society of NuclearMedicine and Molecular Imaging Annual Meeting.
by the Company and a collaborator at the Society of NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting, June 24 – 27, 2023. The presentations included results from an independent clinical study conducted by the University of Augsburg that investigated dosimetry and the therapeutic index for 177Lu-rhPSMA-10.1.
PSMA-PET/CT has the potential to be an effective alternative imaging approach for diagnosing patients with renal cell carcinoma (RCC), a type of kidney cancer, according to a study published May 23 in the Journal of NuclearMedicine. Up to 30% of patients present with metastases at initial diagnosis, according to the authors.
24, 2025 The Society of NuclearMedicine and Molecular Imaging (SNMMI) and the European Association of NuclearMedicine (EANM) have issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET. tim.hodson Tue, 01/28/2025 - 12:06 Jan.
The findings are described in European Urology and were presented at the American Society of Clinical Oncology and Society of NuclearMedicine & Molecular Imaging annual meetings in 2022. For more information: [link] Wednesday, July 26, 2023 - 20:36
Alpha-emitting astatine-211 (At-211) may open the door to new targeted radioimmunotherapy for treating blood cancer, according to research presented June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) in Toronto. The studies support further clinical investigation.
and European nuclearmedicine organizations have released joint guidelines on the use of fibroblast activation protein (FAP)-PET imaging in cancer patients. The guidelines were published in the January issue of the Journal of NuclearMedicine.
Both FUO and IUO can be caused by a wide range of pathological processes, from malignancies, infections, and granulomatous and inflammatory diseases, to miscellaneous causes. Inflammation of unknown origin (IUO) is defined as prolonged and perplexing inflammation with temperatures below 38.3 °C.
Oftentimes, this is because inflammatory breast cancer presents with unique symptoms. Positron Emission Tomography (a PET scan) uses nuclearmedicine to detect metabolic signals emitted by cancer cells. IBC patients experience rapid swelling, changing skin texture, induration, tenderness, and warmth.
Avoidable differences in disease burden and outcomes that socially disadvantaged individuals may experience manifest in nearly all areas of radiology, from emergency imaging, neuroradiology, and nuclearmedicine to image-guided interventions and imaging-based cancer screening, the group noted.
Employing a hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) model to assess predictive features of Alzheimer’s disease (AD), researchers noted a 100 percent sensitivity rate and a 93 percent sensitivity rate for distinguishing between AD and normal cognition, according to a study presented at the recent Society of Nuclear (..)
milla1cf Wed, 05/15/2024 - 19:01 May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., population will have some form of heart disease by 2035, resulting in total costs exceeding $1 trillion. Heart disease is largely preventable, but many people don’t understand their risk until it is too late.
A new AI PET/CT tool can assess patient cancer risk, predict tumor response, and estimate survival, according to research findings delivered June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting in Toronto.
African American men with metastatic castrate-resistant prostate cancer (mCRPC) appear to respond more favorably than white men to treatment with radium-223 (Ra-223) dichloride, according to a study presented at RSNA. with the incidence of disease among African American men approximately 70% higher than in Caucasian men.
Thorwarth, MD, FACR, Chief Executive Officer of the American College of Radiology (ACR) presented testimony to the U.S. Excerpts from the testimony presented by Thorwath, ACR CEO since 2014, specifically addressing the four significant examples of NIH funding which has advanced ACR’s work and patient care follow.
In photon-counting CT technology developments, GEHC said that researchers at Stanford Medicine have begun scanning human subjects using its photon-counting CT prototype. Interventional In image-guided surgery activities, GEHC showcased two new AI applications previously presented at ECR 2023. MRI GEHC unveiled Signa Champion, a 1.5-tesla,
We also expect to see the full Phase 1 results presented at a scientific meeting in 2025." "The Front loading radioactivity and extending the time on therapy may lengthen time to disease progression. Journal of NuclearMedicine (2024). "We remain on track for the opening of Phase 2 in the next few months.
PET/CT reveals a connection between cardiovascular disease (CVD) and cognitive impairment, according to research presented at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) meeting.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content